MDT

87.56

+0.44%↑

A

114.42

-2.15%↓

VEEV

160

-7.43%↓

HQY

83.34

+1.87%↑

TLRY

6.65

-1.92%↓

MDT

87.56

+0.44%↑

A

114.42

-2.15%↓

VEEV

160

-7.43%↓

HQY

83.34

+1.87%↑

TLRY

6.65

-1.92%↓

MDT

87.56

+0.44%↑

A

114.42

-2.15%↓

VEEV

160

-7.43%↓

HQY

83.34

+1.87%↑

TLRY

6.65

-1.92%↓

MDT

87.56

+0.44%↑

A

114.42

-2.15%↓

VEEV

160

-7.43%↓

HQY

83.34

+1.87%↑

TLRY

6.65

-1.92%↓

MDT

87.56

+0.44%↑

A

114.42

-2.15%↓

VEEV

160

-7.43%↓

HQY

83.34

+1.87%↑

TLRY

6.65

-1.92%↓

Search

Cytek Biosciences Inc

Chiusa

SettoreSettore sanitario

4.67 1.52

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

4.58

Massimo

4.79

Metriche Chiave

By Trading Economics

Entrata

-39M

-44M

Vendite

9.8M

62M

Margine di Profitto

-70.929

Dipendenti

702

EBITDA

4M

-263K

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+35.87% upside

Dividendi

By Dow Jones

Utili prossimi

7 mag 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

20M

581M

Apertura precedente

3.15

Chiusura precedente

4.67

Notizie sul Sentiment di mercato

By Acuity

50%

50%

168 / 349 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

Cytek Biosciences Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

8 apr 2026, 20:44 UTC

Utili

Costco Reports 11% Growth in March Sales

8 apr 2026, 23:51 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

8 apr 2026, 23:51 UTC

Discorsi di Mercato

Nikkei May Rise on Hopes for Talks to End Iran War -- Market Talk

8 apr 2026, 23:36 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Gold Edges Lower on Likely Technical Correction -- Market Talk

8 apr 2026, 22:56 UTC

Discorsi di Mercato

Ramelius Resources May Downgrade Cost Guidance This Month -- Market Talk

8 apr 2026, 22:45 UTC

Discorsi di Mercato

Constellation Brands Points to Continuing Challenges Among Hispanic Consumers -- Market Talk

8 apr 2026, 22:17 UTC

Discorsi di Mercato

Applied Digital Says Its Holding Out for Quality Customers -- Market Talk

8 apr 2026, 21:52 UTC

Principali Notizie su Eventi

A Closer Look at Iran's 10 Demands -- and Which the U.S. Might Accept -- Update

8 apr 2026, 21:24 UTC

Utili

FedEx Freight Aims for 12% Profit Growth. How That Compares to the Leader. -- Barrons.com

8 apr 2026, 21:01 UTC

Principali Notizie su Eventi

Oil Prices Tumble Despite Conflicting Reports About the Strait of Hormuz -- Barrons.com

8 apr 2026, 20:50 UTC

Discorsi di Mercato

Energy & Utilities Roundup: Market Talk

8 apr 2026, 20:43 UTC

Acquisizioni, Fusioni, Takeovers

Oracle Is Expressing No Opinion and Is Neutral as to Whether Stockholders Should Tender Their Shrs in Response to TRC's Offer >ORCL

8 apr 2026, 20:43 UTC

Acquisizioni, Fusioni, Takeovers

Oracle Does Not Endorse TRC's Mini-Tender Offer or the Offer Documentation >ORCL

8 apr 2026, 20:43 UTC

Acquisizioni, Fusioni, Takeovers

Oracle: Offer Represents Less Than 0.04% of Outstanding Common Stk >ORCL

8 apr 2026, 20:42 UTC

Acquisizioni, Fusioni, Takeovers

Oracle: TRC Offer Is to Purchase Up to 1M Shrs of Common Stk at $140.50/Shr in Cash >ORCL

8 apr 2026, 20:42 UTC

Acquisizioni, Fusioni, Takeovers

Oracle Received Notice of Unsolicited Mini-Tender Offer by TRC Dated March 24 >ORCL

8 apr 2026, 20:42 UTC

Acquisizioni, Fusioni, Takeovers

Oracle Responds to TRC Cap Mini-Tender Offer

8 apr 2026, 20:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

8 apr 2026, 20:11 UTC

Acquisizioni, Fusioni, Takeovers

Intel Corp.: Repurchased 49% Equity Interest in JV Related to Intel's Fab 34 in Ireland >INTC

8 apr 2026, 20:11 UTC

Acquisizioni, Fusioni, Takeovers

Intel Corp.: $14.2B Repurchase Price Financed with Cash on Hand and a Bridge Loan of $6.5B >INTC

8 apr 2026, 20:11 UTC

Acquisizioni, Fusioni, Takeovers

Intel Corp.: Repurchased JV Stake From Apollo-Managed Funds and Affiliates >INTC

8 apr 2026, 19:44 UTC

Utili

These Companies Pay 5% Dividend Yields, and They're Hiking Them Too -- Barrons.com

8 apr 2026, 19:16 UTC

Discorsi di Mercato

Hogs Follow Cutout Prices Lower -- Market Talk

8 apr 2026, 19:02 UTC

Discorsi di Mercato

Global Energy Roundup: Market Talk

8 apr 2026, 19:02 UTC

Discorsi di Mercato

Oil Futures Plunge as Cease-Fire Raises Hopes for Restored Supply -- Market Talk

8 apr 2026, 18:58 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Fall in Line With Slump in Oil -- Market Talk

8 apr 2026, 18:51 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

8 apr 2026, 18:51 UTC

Discorsi di Mercato

Levi Strauss CEO Says Expanded Offerings, DTC Focus Are Working -- Market Talk

8 apr 2026, 18:14 UTC

Principali Notizie su Eventi

Fed Minutes Suggest a Lengthy Iran War Could Lead to Rate Hikes -- Barrons.com

8 apr 2026, 18:05 UTC

Principali Notizie su Eventi

Oil Prices Continue to Tumble After Cease-Fire Despite Slow Reopening of Strait of Hormuz -- Barrons.com

Confronto tra pari

Modifica del prezzo

Cytek Biosciences Inc Previsione

Obiettivo di Prezzo

By TipRanks

35.87% in crescita

Previsioni per 12 mesi

Media 6.25 USD  35.87%

Alto 7.5 USD

Basso 5 USD

Basato su 2 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Cytek Biosciences Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

2 ratings

1

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

3.7 / 3.8Supporto e resistenza

A breve termine

Weak Bullish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

168 / 349 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
help-icon Live chat